MESOBLAST LIMITED

MESO ·Healthcare, Drug Manufacturers - General, Australia
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $17.2M $5.9M $7.5M $10.2M $7.4M $32.2M $16.7M $17.3M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development
SG&A Expense
Operating Income $-80.1M $-67.5M $-62.7M $-74.7M $-83.7M $-72.6M $-87.1M $-64.1M
Operating Margin -465.5% -1,143.5% -835.3% -731.4% -1,125.8% -225.9% -520.6% -369.9%
Interest Expense $21.8M $20.7M $19.4M $16.9M $15.9M $14.7M $11.7M $1.8M
Pretax Income $-101.8M $-88.1M $-82.1M $-91.6M $-99.6M $-87.4M $-98.8M $-66.0M
Income Tax Expense $330.0K $-191.0K $-212.0K $-239.0K $-819.0K $-9.4M $-9.0M $-30.7M
Net Income $-102.1M $-88.0M $-81.9M $-91.3M $-98.8M $-77.9M $-89.8M $-35.3M
Net Margin -593.9% -1,490.3% -1,091.7% -894.6% -1,329.2% -242.4% -537.0% -203.5%
EPS (Basic) $-0.08 $-0.09 $-0.11 $-0.13 $-0.16 $-0.15 $-0.18 $-0.08
EPS (Diluted) $-0.08 $-0.09 $-0.11 $-0.13 $-0.16 $-0.15 $-0.18 $-0.08
Shares Outstanding (Basic) 1.28B 1.14B 814.2M 650.5M 648.7M 583.9M 498.6M 482.6M
Shares Outstanding (Diluted) 1.28B 1.14B 814.2M 650.5M 648.7M 583.9M 498.6M 482.6M
Dividends Per Share
← Newer Page 1 of 2 Older →